Glucagon-like peptide-1 counteracts the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T 15

Biochemical and Biophysical Research Communications

Volumn 398, Issue 3, 2010, Pages 462-466

  Puddu, A ^a   Storace, D ^a   Durante, A ^a   Odetti, P ^a   Viviani, G L ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Advanced Glycation End Products; Diabetes; Glucagon like peptide 1; Pancreatic beta cells

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; INSULIN RELEASE; OXIDATION REDUCTION REACTION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

CELL LINE; CELL SURVIVAL; CYTOPROTECTION; GLUCAGON-LIKE PEPTIDE 1; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN-SECRETING CELLS;

EID: 77955273235     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.06.100     Document Type: Article

References (27)

1. Stumvoll M., Goldstein B.J., VanHaeften T.W. Type 2 diabetes principles of pathogenesis and therapy. Lancet 2005, 365:1333-1346.
2. Singh R., Barden A., Mori T., Beilin L. Advanced glycation end-products:a review. Diabetologia 2001, 44:129-146.
3. Ulrich P., Cerami A. Protein glycation diabetes, and aging. Recent Prog. Horm. Res. 2001, 56:1-21.
4. Schleicher E.D., Wagner E., Nerlich A.G. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 1997, 99:457-468.
5. Jakus V., Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol. Res. 2004, 53:131-142.
6. Luciano Viviani G., Puddu A., Sacchi G., Garuti A., Storace D., Durante A., Monacelli F., Odetti P. Glycated fetal calf serum affects the viability of an insulin-secreting cell line in vitro. Metabolism 2008, 57:163-169.
7. Puddu A., Storace D., Odetti P., Viviani G.L. Advanced glycation end-products affect transcription factors regulating insulin gene expression. Biochem Biophys Res Commun 2010, 395:122-125.
8. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
9. Wajchenberg B.L. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr. Rev. 2007, 28:187-218.
10. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
11. Farilla L., Hui H., Bertolotto C., Kang E., Bulotta A., Di Mario U., Perfetti R. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002, 143:4397-4408.
12. Bulotta A., Hui H., Anastasi E., Bertolotto C., Boros L.G., Di Mario U., Perfetti R. Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1. J. Mol. Endocrinol. 2002, 29:347-360.
13. Farilla L., Bulotta A., Hirshberg B., Li Calzi S., Khoury N., Noushmehr H., Bertolotto C., Di Mario U., Harlan D.M., Perfetti R. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003, 144:5149-5158.
14. Hui H., Nourparvar A., Zhao X., Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003, 144:1444-1455.
15. Urusova I.A., Farilla L., Hui H., D'Amico E., Perfetti R. GLP-1 inhibition of pancreatic islet cell apoptosis. Trends Endocrinol. Metab. 2004, 15:27-33.
16. D'Amico E., Hui H., Khoury N., Di Mario U., Perfetti R. Pancreatic beta-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs. J. Mol. Endocrinol. 2005, 34:377-390.
17. Ishibashi Y., Matsui T., Takeuchi M., Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 2010, 391:1405-1408.
18. Odetti P., Fogarty J., Sell D.R., Monnier V.M. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992, 41:153-159.
19. Wang Y., Egan J.M., Raygada M., Nadiv O., Roth J., Montrose-Rafizadeh C. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology 1995, 136:4910-4917.
20. Drucker D.J., Philippe J., Mojsov S., Chick W.L., Habener J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. USA 1987, 84:3434-3438.
21. Hussain M.A., Habener J.F. Glucagon-like peptide 1 increases glucose-dependent activity of the homeoprotein IDX-1 transactivating domain in pancreatic beta-cells. Biochem Biophys Res Commun. 2000, 274:616-619.
22. Bierhaus A., Nawroth P.P. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation immune responses and diabetes mellitus and its complications. Diabetologia 2009.
23. Li L., El-Kholy W., Rhodes C.J., Brubaker P.L. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 2005, 48:1339-1349.
24. Tiedge M., Lortz S., Drinkgern J., Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 1997, 46:1733-1742.
25. Tiedge M., Lortz S., Munday R., Lenzen S. Complementary action of antioxidant enzymes in the protection of bioengineered insulin-producing RINm5F cells against the toxicity of reactive oxygen species. Diabetes 1998, 47:1578-1585.
26. Lu S.C. Regulation of glutathione synthesis. Curr. Top. Cell. Regul. 2000, 36:95-116.
27. Kimura R., Okouchi M., Fujioka H., Ichiyanagi A., Ryuge F., Mizuno T., Imaeda K., Okayama N., Kamiya Y., Asai K., Joh T. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience 2009, 162:1212-1219.